JP2020535803A5 - - Google Patents

Download PDF

Info

Publication number
JP2020535803A5
JP2020535803A5 JP2020516666A JP2020516666A JP2020535803A5 JP 2020535803 A5 JP2020535803 A5 JP 2020535803A5 JP 2020516666 A JP2020516666 A JP 2020516666A JP 2020516666 A JP2020516666 A JP 2020516666A JP 2020535803 A5 JP2020535803 A5 JP 2020535803A5
Authority
JP
Japan
Prior art keywords
virus
vector
nucleic acid
promoter
rnai
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020516666A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020535803A (ja
JP7248658B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/052221 external-priority patent/WO2019060726A1/en
Publication of JP2020535803A publication Critical patent/JP2020535803A/ja
Publication of JP2020535803A5 publication Critical patent/JP2020535803A5/ja
Application granted granted Critical
Publication of JP7248658B2 publication Critical patent/JP7248658B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020516666A 2017-09-22 2018-09-21 バリアントRNAi Active JP7248658B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762561843P 2017-09-22 2017-09-22
US62/561,843 2017-09-22
PCT/US2018/052221 WO2019060726A1 (en) 2017-09-22 2018-09-21 Variant rnai

Publications (3)

Publication Number Publication Date
JP2020535803A JP2020535803A (ja) 2020-12-10
JP2020535803A5 true JP2020535803A5 (https=) 2021-10-28
JP7248658B2 JP7248658B2 (ja) 2023-03-29

Family

ID=64017428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020516666A Active JP7248658B2 (ja) 2017-09-22 2018-09-21 バリアントRNAi

Country Status (19)

Country Link
US (3) US11603529B2 (https=)
EP (1) EP3684932A1 (https=)
JP (1) JP7248658B2 (https=)
KR (1) KR102686857B1 (https=)
CN (1) CN111356763B (https=)
AR (1) AR113134A1 (https=)
AU (2) AU2018335410B2 (https=)
BR (1) BR112020005569A2 (https=)
CA (1) CA3076191A1 (https=)
CO (1) CO2020003187A2 (https=)
IL (1) IL273394B2 (https=)
MX (2) MX2020003095A (https=)
MY (1) MY205041A (https=)
PH (1) PH12020550117A1 (https=)
SG (1) SG11202002488UA (https=)
TW (1) TWI902656B (https=)
UY (1) UY37897A (https=)
WO (1) WO2019060726A1 (https=)
ZA (1) ZA202001586B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170406A (es) 2015-02-10 2017-11-14 Genzyme Corp Arni variante
KR102427379B1 (ko) 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. 헌팅톤 질환을 치료하기 위한 조성물 및 방법
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. ハンチントン病治療組成物および方法
CN111356763B (zh) 2017-09-22 2024-03-12 建新公司 变体RNAi
CN112980837B (zh) * 2019-12-13 2023-07-04 深圳艾码生物科技有限公司 一种抑制HTT基因表达的siRNA及其前体和应用
US12227754B2 (en) * 2020-04-07 2025-02-18 Lung Biotechnology Pbc Adenoviral expression vector and methods and cell lines for production
EP4317434A4 (en) * 2021-03-30 2025-04-16 Nanjing University RNA DELIVERY SYSTEM FOR THE TREATMENT OF HUNTINGTON'S DISEASE
EP4619018A2 (en) * 2022-11-16 2025-09-24 Forge Biologics, Inc. Adenoviral helper plasmid
WO2025160434A1 (en) * 2024-01-26 2025-07-31 Genzyme Corporation Artificial micrornas targeting huntington's disease
WO2025250616A1 (en) * 2024-05-29 2025-12-04 The Regents Of The University Of California Methods and materials for treating huntington's disease

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0931158A1 (en) 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2379166C (en) 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
ATE318923T1 (de) 2000-06-01 2006-03-15 Univ North Carolina Doppelsträngige parvovirus-vektoren
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
MX359371B (es) 2001-11-13 2018-09-25 Univ Pennsylvania Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
US20050255086A1 (en) * 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
JP2004101787A (ja) 2002-09-09 2004-04-02 Fuji Xerox Co Ltd 画像形成装置及び現像装置
CA2881743A1 (en) 2002-09-25 2004-04-08 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
US7589189B2 (en) 2003-05-14 2009-09-15 Japan Science And Technology Agency Inhibition of the expression of huntingtin gene
EP1844148A2 (en) * 2005-01-31 2007-10-17 University of Iowa Research Foundation Nucleic acid silencing of huntington's disease gene
WO2006119432A2 (en) 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
US7902352B2 (en) 2005-05-06 2011-03-08 Medtronic, Inc. Isolated nucleic acid duplex for reducing huntington gene expression
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
US8173614B2 (en) * 2007-01-03 2012-05-08 Medtronic, Inc. Therapeuting compositions comprising an RNAi agent and a neurotrophic factor and methods of use thereof
EP2152874A2 (en) 2007-04-26 2010-02-17 University of Iowa Research Foundation Rna interference suppression of neurodegenerative diseases and methods of use thereof
DK2164967T3 (en) 2007-05-31 2015-10-19 Univ Iowa Res Found Reduction of off-target rna interferenstoksicitet
CA2711585A1 (en) 2008-02-04 2009-08-13 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
AU2009214837A1 (en) 2008-02-14 2009-08-20 Michael Paul Marie Gantier Immunostimulatory siRNA molecules
FR2929292A1 (fr) * 2008-03-28 2009-10-02 Exonhit Therapeutics S A Sa Procede et methodes de diagnostic de la maladie d'alzheimer
US8796238B2 (en) 2009-09-17 2014-08-05 Sigma-Aldrich Co. Llc Short RNA mimetics
EP2561073B1 (en) 2010-04-23 2016-08-24 University of Massachusetts Cns targeting aav vectors and methods of use thereof
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
TR201908020T4 (tr) 2011-02-17 2019-06-21 Univ Pennsylvania Doku özgüllüğünü değiştirmek ve aav9-aracılı gen transferini geliştirmek için bileşimler ve yöntemler.
WO2013130824A1 (en) * 2012-02-29 2013-09-06 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
CN103224556B (zh) * 2013-01-31 2015-04-15 清华大学 亨廷顿舞蹈症的靶位蛋白质及其编码基因和应用
US9550989B2 (en) 2013-10-03 2017-01-24 Washington University Rational design of microRNA-siRNA chimeras for multi-functional target suppression
WO2015070212A1 (en) * 2013-11-11 2015-05-14 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
PL3628334T3 (pl) * 2014-03-21 2023-12-18 Genzyme Corporation Terapia genowa w retinopatii barwnikowej
LT3137497T (lt) 2014-05-02 2021-07-26 Genzyme Corporation Aav vektoriai, skirti tinklainės ir cns genų terapijai
EP3146051B8 (en) * 2014-05-20 2019-11-27 University of Iowa Research Foundation Huntington's disease therapeutic compounds
HRP20190992T1 (hr) 2014-12-24 2019-09-20 Uniqure Ip B.V. Suprimiranje gena za huntingtin inducirano s rnai
CR20170406A (es) 2015-02-10 2017-11-14 Genzyme Corp Arni variante
KR102427379B1 (ko) * 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. 헌팅톤 질환을 치료하기 위한 조성물 및 방법
CN111356763B (zh) 2017-09-22 2024-03-12 建新公司 变体RNAi
KR102931619B1 (ko) * 2018-08-03 2026-02-26 젠자임 코포레이션 알파-시뉴클레인에 대한 변이형 RNAi

Similar Documents

Publication Publication Date Title
JP2020535803A5 (https=)
JP2018506304A5 (https=)
JP2021534814A5 (https=)
IL273394B1 (en) Variant rnai
JP2020019772A5 (https=)
JP2020114235A5 (https=)
JP2025063053A5 (https=)
JP2021106619A5 (https=)
JP2022549380A5 (https=)
JP2017535266A5 (https=)
IL292999A (en) Compositions and methods of treating amyotrophic lateral sclerosis (als)
RU2018140499A (ru) Способы и композиции для лечения хореи гентингтона
JP2019533439A5 (https=)
JP2022524434A5 (https=)
JP2017509632A5 (https=)
JP2023515692A5 (https=)
JP2022525302A5 (https=)
JP2020519284A5 (https=)
JP2022551744A5 (https=)
JP2024099770A5 (https=)
JP2021522836A5 (https=)
JP2023541443A5 (https=)
JP2024508696A5 (https=)
IL292264B1 (en) Aav transfer cassette
JP2023524024A5 (https=)